Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13639525 | 0.84 | CKS1B (0.42) | ALDH1A1KDM4ECKS1BSKP1SKP2 | |
| SCHEMBL22694387 | 0.80 | ALDH1A1 (0.40) | ALDH1A1KDM4ESMN1; SMN2CKS1BSKP1 | |
| SCHEMBL12677181 | 0.80 | CKS1B (0.42) | ALDH1A1KDM4ELMNACKS1BSKP1 | |
| SCHEMBL22722665 | 0.80 | CKS1B (0.39) | ALDH1A1KDM4ELMNAHPGDCKS1B | |
| SCHEMBL12670578 | 0.80 | CNR2 (0.40) | ALDH1A1KDM4EHPGDCKS1BSKP1 | |
| SCHEMBL22694425 | 0.80 | PDE10A (0.39) | KDM4ECKS1BSKP1SKP2KMT2A | |
| SCHEMBL1330773 | 0.78 | SLC9A1 (0.39) | ALDH1A1KDM4ELMNAHPGDSMN1; SMN2 | |
| SCHEMBL12309910 | 0.71 | HPGD (0.45) | ALDH1A1KDM4ELMNAHPGDSMN1; SMN2 | |
| SCHEMBL22694400 | 0.70 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDSMN1; SMN2CKS1B | |
| SCHEMBL22461325 | 0.69 | L3MBTL1 (0.51) | ALDH1A1KDM4ELMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810596-B1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3810596-A1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| CN-112513030-A | Quinoline derivatives as tyrosine kinase inhibitors | 里格尔药品股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851093-B2 | Tyrosine kinase inhibitors | TYRO3, RET, AXL | ALDH1A1 2120/4885KDM4E 743/4885LMNA 3620/4885 |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | TYRO3, RET, AXL | ALDH1A1 2120/4885KDM4E 743/4885LMNA 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.